TREATMENT VARIATION COMPLICATES REAL-WORLD PHARMACOECONOMICS: DAILY CLINICAL PRACTICE OF BORTEZOMIB IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA

被引：1
|
作者：
Franken, M. [1 ]
Gaultney, J. [1 ]
Huijgens, P. [2 ]
Redekop, W. K. [1 ]
Uyl-de Groot, C. A. [1 ]
机构：
[1] Erasmus Univ, Med Ctr, Rotterdam, Netherlands
[2] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands
来源：
VALUE IN HEALTH | 2009年 / 12卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(10)74098-5
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A225 / A225
页数：1
相关论文
共 50 条
  • [31] Real-World Study of Treatment Patterns in Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM) in the US
    Wang, Peter Feng
    Sansbury, Leah
    DerSarkissian, Maral
    Ferrante, Shannon
    Bhak, Rachel
    Gorsh, Boris
    Zichlin, Miriam L.
    Yee, Christopher W.
    Boytsov, Natalie
    Khanal, Anamika
    Paka, Prani
    Noman, Ahmed
    Duh, Mei Sheng
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S423 - S423
  • [32] Vorinostat Plus Bortezomib for the Treatment of Relapsed/Refractory Multiple Myeloma: Early Clinical Experience
    Weber, Donna
    Badros, Ashraf Z.
    Jagannath, Sundar
    Siegel, David
    Richon, Victoria
    Rizvi, Syed
    Garcia-Vargas, Jose
    Reiser, David
    Anderson, Kenneth C.
    [J]. BLOOD, 2008, 112 (11) : 322 - 322
  • [33] Clinical and Sociodemographic Characteristics of Patients With Relapsed and/or Refractory Multiple Myeloma and Their influence on Treatment in the Real-World Setting in Spain: The CharisMMa Study
    Ocio, Enrique M.
    Montes-Gaisan, Carmen
    Bustamante, Gabriela
    Garzon, Sebastian
    Gonzalez, Esther
    Perez, Ernesto
    Sirvent, Maialen
    Arguinano, Jose Maria
    Gonzalez, Yolanda
    Rios, Rafael
    de Miguel, Dunia
    Grande, Marta
    Fernandez, Alonso
    Naves, Andrea
    Rosinol, Laura
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (04): : E241 - E249
  • [34] Real-World and Clinical Trial Data in Relapsed/Refractory Multiple Myeloma (RRMM): Evaluating Treatment Duration and Comparing Effectiveness and Efficacy
    Richardson, Paul G.
    San Miguel, Jesus F.
    Moreau, Philippe
    Hajek, Roman
    Dimopoulos, Meletios A.
    Palumbo, Antonio
    Luptakova, Katarina
    Skacel, Tomas
    Kumar, Shaji K.
    Anderson, Kenneth C.
    [J]. BLOOD, 2017, 130
  • [35] Belantamab mafodotin for relapsed/refractory multiple myeloma: a real-world observational study update
    Hultcrantz, Malin
    Kleinman, David
    Vij, Ravi
    Escalante, Fernando
    Delforge, Michel
    Kotowsky, Nirali
    Bitetti, Jacopo
    Boytsov, Natalie
    Camadoo-O'Byrne, Leena
    Happ, Lindsey Powers
    Rohman, Mujib
    Germain, Guillaume
    Duh, Mei Sheng
    Laliberte, Francois
    Mahendran, Malena
    Urosevic, Ana
    Lee, Hans
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S185 - S186
  • [36] Real World Evaluation of Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma (RRMM)
    Maringanti, Sireesha Asoori
    Lin, Yi
    Estritis, Stathis
    Martinez-Lopez, Joaquin
    Bansal, Radhika
    Fotiou, Despina
    Corona, Magdalena
    Chhabra, Saurabh
    Brunaldi, Larissa
    Corraes, Andre De Menezes Silva
    Parrondo, Ricardo
    Kapoor, Prashant
    Ailawadhi, Sikander
    Mas, Reyes
    Tamayo, Andrea
    Dimopoulos, Meletios
    Durie, Brian
    Martin, Thomas
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S506 - S507
  • [37] Real-World Disparities in Daratumumab Utilization for Patients with Relapsed or Refractory Multiple Myeloma (MM)
    Maignan, Kathleen
    Backenroth, Daniel
    McQuarrie, Neil A.
    Lipitz, Nicole G.
    Williams, Erin R.
    Carson, Kenneth R.
    [J]. BLOOD, 2018, 132
  • [38] Teclistamab for Relapsed/Refractory Multiple Myeloma: Real-World Experience in an Early Access Program
    Uttervall, Katarina
    Nahi, Hareth
    Kashif, Muhammad
    Lemonakis, Konstantinos
    Rosengren, Sara
    Brolin, Janaki
    Lund, Johan
    Hansson, Markus
    [J]. BLOOD, 2022, 140 : 12605 - 12606
  • [39] Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
    Meera Mohan
    Jorge Monge
    Nishi Shah
    Danny Luan
    Mark Forsberg
    Vineel Bhatlapenumarthi
    Metodi Balev
    Anannya Patwari
    Heloise Cheruvalath
    Divaya Bhutani
    Sharmilan Thanendrarajan
    Binod Dhakal
    Maurizio Zangari
    Samer Al-Hadidi
    Dennis Cooper
    Suzanne Lentzsch
    Frits van Rhee
    Anita D’Souza
    Aniko Szabo
    Carolina Schinke
    Rajshekhar Chakraborty
    [J]. Blood Cancer Journal, 14
  • [40] Safety and Efficacy of Teclistamab in Patients with Relapsed/ Refractory Multiple Myeloma: A Real-World Experience
    Dima, Danai
    Davis, James A.
    Ahmed, Nausheen
    Jia, Xuefei
    Sannareddy, Aishwarya
    Shaikh, Hira
    Shune, Leyla
    Kaur, Gurbakhash
    Khouri, Jack
    Afrough, Aimaz
    Strouse, Christopher
    Lochner, Jonathan
    Mahmoudjafari, Zahra
    Raza, Shahzad
    Valent, Jason
    Anderson Jr, Larry D.
    Anwer, Faiz
    Abdallah, Al-Ola
    Hashmi, Hamza
    [J]. TRANSPLANTATION AND CELLULAR THERAPY, 2024, 30 (03):
12345